Pharmacy Prior Authorization Criteria

Crenessity (crinecerfont)

Indications for Prior Authorization

Crenessity (crinecerfont)

• For diagnosis of Congenital Adrenal Hyperplasia (CAH)
  Indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).

Criteria

Crenessity

Prior Authorization (Initial Authorization)

Length of Approval: 6 Month(s)
For diagnosis of Congenital Adrenal Hyperplasia (CAH)

• Diagnosis of classic 21-hydroxylase deficiency congenital adrenal hyperplasia
AND
• Patient is 4 years of age or older
AND
• Patient is receiving chronic treatment with glucocorticoid (GC) replacement therapy (e.g., dexamethasone, hydrocortisone, methylprednisolone) for adrenal insufficiency as one of the following:
• Both of the following: 
• Patient is 4 to 17 years old
• Daily GC dose is greater than 12 mg/m2/day in hydrocortisone dose equivalents
OR
• Both of the following: 
• Patient is 18 years of age or older
• Daily GC dose is greater than 13 mg/m2/day in hydrocortisone dose equivalents
AND
• Prescribed by an endocrinologist

Crenessity

Prior Authorization (Reauthorization)

Length of Approval: 12 Month(s)
For diagnosis of Congenital Adrenal Hyperplasia (CAH)

• Patient demonstrates positive clinical response to therapy (e.g., lowered androgen levels, reduced daily dose of steroids)
AND
• Patient continues to receive chronic treatment with glucocorticoid (GC) replacement therapy (e.g., dexamethasone, hydrocortisone, methylprednisolone)
AND
• Prescribed by or in consultation with an endocrinologist

P & T Revisions

2025-02-06

References

1. Crenessity Prescribing Information. Neurocrine Biosciences, Inc., San Diego, CA. December 2024.
2. Supplemental Information from Phase 3 trial of crinecerfont in pediatric congenital adrenal hyperplasia. N Engl J Med 2024;391:493-503. Available at: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2404655/suppl_file/nejmoa2404655_appendix.pdf
3. Supplemental Information from Phase 3 trial of crinecerfont in adult congenital adrenal hyperplasia. Phase 3 trial of crinecerfont in adult congenital adrenal hyperplasia. N Engl J Med 2024;391:504-14. Available at: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2404656/suppl_file/nejmoa2404656_appendix.pdf

---

Revision History

• 2025-02-06: New Program.

---